Lutein and Oral Antioxidants Vitamin Supplements for Eye Conditions - prescribing guidance |
Dry Eye Patient Information Leaflet |
GREEN* Self-care policy applies - advise patient to purchase where appropriate [Consider OTC/Self care] |
GREEN* Sno-Tears® 1.4% eye drops [Polyvinyl alcohol] |
GREEN* Hypromellose 0.3% eye drops [AaproMel®, Dew Tear®, Lumecare®] |
GREEN* Clinitas Gel® eye drops [Carbomer] |
GREEN* HYLO-NIGHT® eye ointment (formerly VitA-POS® eye ointment) |
GREEN* Lacri-Lube eye ointment |
AMBER llube® eye drops |
AMBER Hylo-Forte® eye drops (Consultant initiation only, reserved for dexterity issues) |
[Self-care should be considered for mild/moderate dry eye not associated with a co-morbidity] |
AMBER Systane® BALANCE lubricant eye drops (Specialist initiation only for Dry eye symptoms associated with |
Meibomian gland dysfunction) |
AMBER Ciclosporin (Ikervis®) unit dose eye drops - PRESCRIBE BY BRAND |
Ciclosporin for treatment of dry eye disease that has not improved despite treatment with artificial tears is |
recommended as an option by NICE. NICE TA369 |
AMBER Sodieye® 5% PF eye drops [Sodium Chloride 5% eye drops] PRESCRIBE BY BRAND |
AMBER Ciclosporin 0.1% eye drops 0.3ml unit dose (Verkazia®) -- Specialist initiation |
RED Cross Linked Hyaluronic Acid & Co Enzyme Q10 (VisuXL®) Specialist use only |
RED Carbomer single use eye gel (Viscotears® eye gel 0.6ml unit dose) NICU use only |
|
Severe Dry Eye Only |
GREEN* Evolve HA® eye drops (preservative free) |
[Self-care should be considered for mild/moderate dry eye not associated with a co-morbidity] |
GREEN* Xailin HA® (sodium hyaluronate 0.2% Preservative Free) |
[Self-care should be considered for mild/moderate dry eye not associated with a co-morbidity] |
GREEN* Blink® Intensive Tears** 10ml and 0.4ml unit dose drops [Sodium hyaluronate 0.2%) |
**[1st line choice hyaluronate in Primary Care] |
|
BACK to main chapter |
|
11.8.2 Ocular diagnostic and peri-operative preparations and photodynamic treatment |
Ocular diagnostic preparations |
AMBER Apraclonidine eye drops 0.5% |
RED Fluorescein unit dose eye drops 1%, 2% |
RED Proxymetacaine & fluorescein unit dose eye drops 0.5% |
|
Ocular peri-operative drugs |
RED Balanced Salt Solution® |
AMBER Diclofenac unit dose eye drops 0.1% |
AMBER Ketorolac eye drops 0.5% |
RED Miochol-E® solution for intra-ocular irrigation |
RED Sodium hyaluronate injection 10mg/ml, 14mg/mL, 23mg/mL |
|
Approved for specific use in ophthalmolgy for volume enhancement of post-enucleation socket syndrome: |
RED Hyaluronic acid injection (Restylane Sub-Q,® Juvederm®) |
|
Approved for use in opthalmology for those at higher risk of developing post-surgical cystoid macular oedema: |
RED Bromfenac eye drops (Yellox®) |
|
Subfoveal choroidal neovas cullarisation |
For use as per NICE guidance only. |
RED Verteporfin injection 15mg vial |
|
11.8.2.3 Subfoveal choroidal neovascularisation |
Aflibercept |
Approved for use in line with NICE guidance |
NICE TA294 Wet age-related macular degeneration |
NICE TA305 Visual Impairment caused by macular oedema secondary to central retinal vein occlusion |
NICE TA346 Treatment for some people with sight problems caused by diabetic macular oedema |
NICE TA486 An option for treating visual impairment because of myopic choroidal neovascularisation in adults, |
only if the company provides aflibercept with the discount agreed in the patient access scheme |
RED Aflibercept [Eylea 2mg/50microlitres solution for intravitreal injection] (NHS England Commissioned) |
|
Vitreomacular traction |
Ocriplasmin for use in accordance with NICE guidance as an option in NICE TA297 |
RED Ocriplasmin concentrate for solution for intravitreal injection 2.5mg/mL |
(Each vial contains 0.5 mg of ocriplasmin in 0.2 ml solution) |
|
Ranibizumab |
Approved for use in accordance with NICE guidance: |
NICE TA283 Visual Impairment caused by Macular oedema secondary to retinal vein occlusion |
NICE TA274 Diabetic macular oedema (DMO) |
NICE TA155 Wet age-related macular degeneration (AMD) |
NICE TA298 Choroidal neovascularisation associated with pathological myopia |
|
RED Ranibizumab solution for intravitreal injection 10mg/mL vial |
|
Brolucizumab |
Wet age-related macular degeneration |
NICE TA672 Recommended as an option for treating wet age-related macular degeneration in adults [as per guidance] |
RED Brolucizumab solution for injection pre-filled syringes 19.8mg/0.165ml |
CCG Commissioned Blueteq form required |
|
Faricimab |
Wet age-related macular degeneration |
NICE TA800 Recommended as an option for treating wet age-related macular degeneration in adults, only if: |
> the eye has a best-corrected visual acuity between 6/12 and 6/96 |
> there is no permanent structural damage ti the central fovea |
> the lesion size is 12 disc areas or less in greatest linear dimension |
> there are signs of recent disease progression (for example, blood vessel growth as shown by fluorescein |
angiography, or recent visual acuity changes) |
> the company provides faricimab according to the commercial arrangement |
ICB Commissioned (formerly CCG) Blueteq form required |